Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AI500 is a **topical medical device** formulated as a monodose hydrogel for direct skin application, used to relieve pain caused by the inflammatory response in muscles, joints, and adjacent tissues to improve movement and function[1][3]. The gel contains **SH-Polypeptide-6**, a recombinant peptide derived from Interleukin-10 (IL-10), embedded in **hyaluronic acid**. SH-Polypeptide-6 mimics the anti-inflammatory activity of IL-10 by modulating NF-kB signaling and downregulating pro-inflammatory cytokines (TNF, IL-6, IL-1, IL-8), thus reducing pain and inflammation. Additionally, it inhibits protein tyrosine phosphatase 1B, potentially alleviating muscle pain and spasms. Unlike IL-10, SH-Polypeptide-6 provides rapid tissue bioavailability at the application site. AI500 is indicated for acute and chronic knee pain and musculoskeletal conditions, with clinical data supporting pain relief and improved function in patients with osteoarthritis and other knee problems. The product is non-invasive, applied via a patch, and demonstrates a favorable safety profile with minimal adverse events[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AI500.